NR1H4 and type 2 diabetes mellitus: The 3-day treatment with metformin in newly diagnosed patients with type 2 diabetes reduced Bacteroides fragilis and increased the bile acid glycoursodeoxycholic acid (GUDCA) in the gut, which were accompanied by inhibition of intestinal farnesoid X receptor (FXR) signaling [16].